SPX3,825.33+39.95 1.06%
DIA310.85+3.03 0.98%
IXIC11,127.85+99.11 0.90%

BRIEF-Caribou Biosciences Says Positive Additional Data From CB-010 Allogeneic CAR-T Cell Therapy Phase 1 Antler Trial

reuters.com · 06/10/2022 03:04
BRIEF-Caribou Biosciences Says Positive Additional Data From CB-010 Allogeneic CAR-T Cell Therapy Phase 1 Antler Trial

- Caribou Biosciences Inc CRBU:

  • CARIBOU BIOSCIENCES REPORTS POSITIVE ADDITIONAL DATA FROM CB-010 ALLOGENEIC CAR-T CELL THERAPY PHASE 1 ANTLER TRIAL AT THE EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2022 HYBRID CONGRESS

  • CARIBOU BIOSCIENCES - BASED ON PROMISING INITIAL SAFETY PROFILE AND CLINICAL ACTIVITY, ANTLER PHASE 1 TRIAL ENROLLING PATIENTS AT DOSE LEVEL 2

  • ADDITIONAL ANTLER DATA EXPECTED BY YEAR-END 2022

Source text for Eikon: ID:nGNX4ZQ05W

Further company coverage: CRBU


((Reuters.Briefs@thomsonreuters.com;))